Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tamolarizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.65 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.65 |
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 0.58 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.58 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.58 |
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.54 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.54 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.54 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.52 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamolarizine SCHEMBL29352586 | 1.00 | MEN1 (0.65) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| Tamolarizine SCHEMBL1230722 | 1.00 | MEN1 (0.65) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| Tamolarizine SCHEMBL331314 | 0.99 | KMT2A (0.67) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| Hydrochloric Acid SCHEMBL10495000 | 0.88 | KMT2A (0.65) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| SCHEMBL10985091 | 0.87 | KMT2A (0.67) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| Hydrochloric Acid SCHEMBL10990138 | 0.82 | MEN1 (0.97) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| Hydrochloric Acid SCHEMBL9769781 | 0.82 | ALDH1A1 (0.50) | KMT2AALDH1A1GAATDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7265661 | 0.81 | KMT2A (0.59) | MEN1KMT2AOPRM1OPRD1IGF1R | |
| Hydrochloric Acid SCHEMBL10337869 | 0.81 | ALDH1A1 (0.54) | MEN1KMT2AOPRM1OPRD1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7272686 | 0.81 | MEN1 (0.57) | MEN1KMT2AOPRM1OPRD1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) | 2011-07-14 | — | — | US | disclosed |
| WO-2010046908-A2 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) | 2010-04-29 | — | — | WO | disclosed |
| EP-0354068-B1 | Optically active piperazine derivative | NIPPON CHEMIPHAR CO (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0256890-B1 | PHARMACEUTICAL COMPOSITION FOR PROTECTION OF BRAIN CELLS | NIPPON CHEMIPHAR CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4978666-A | INCREASED CEREBRAL CIRCULATION; ANTICOAGULANTS | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-12-18 | — | — | US | disclosed |
| EP-0354068-A2 | Optically active piperazine derivative | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| US-4835155-A | Process for protection of brain cells | NIPPON CHEMIPHAR CO., LTD. (JP) | 1989-05-30 | — | — | US | disclosed |
| EP-0256890-A2 | Pharmaceutical composition for protection of brain cells | NIPPON CHEMIPHAR CO., LTD. (JP) | 1988-02-24 | — | — | EP | disclosed |
| US-4528194-A | 2-(4-Diphenylmethylpiperazinyl)-1-phenyl alkanol or their salts, a process for their production and a cerebral circulation-improving drug | NIPPON CHEMIPHAR CO., LTD. (JP) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | ALK, WIZ, HACL2 | OPRM1 332/4885OPRD1 619/4885ADRA1D 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.